 |
|
|
| |
Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial
|
| |
| |
EASL 2023 June 23 Vienna
Edward J. Gane1, Alina Jucov2,3, Marta Dobryanksa4,5, Ki Tae yoon6, Tien Huey Lim7, Andre Arizpe8, Daniel Cloutier8,
Michael Chattergoon8, Shenghua Mao8, Sneha V. Gupta8,
Gregory Camus8, Carey Hwang8, Young-Suk Lim9
|
| |
|
|
|
|
|
